Literature DB >> 23810943

The skeleton in the closet.

Frederick S Kaplan1.   

Abstract

The origins of fibrodysplasia ossificans progressiva (FOP) in human history are unknown but the condition has been well described since Freke's account in 1740. Important contributions by physicians and scientists in the past two and a half centuries have converged on the remarkable skeleton of Harry Eastlack at The Mutter Museum of The College of Physicians in Philadelphia.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACVR1/ALK2; BMP; FOP; Fibrodysplasia ossificans progressiva; activin A receptor, type I/activin receptor-like kinase 2; bone morphogenetic protein; fibrodysplasia ossificans progressiva

Mesh：

Substances：

Year:  2013        PMID： 23810943      PMCID： PMC4586120          DOI： 10.1016/j.gene.2013.06.022

Source DB:  PubMed          Journal:  Gene        ISSN： 0378-1119            Impact factor:   3.688


  19 in total

1.  Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting.

Authors:  J Kaplan; F S Kaplan; E M Shore
Journal:  Gene Ther       Date:  2011-10-20       Impact factor: 5.250

2.  A CONTRIBUTION TO THE STUDY OF MYOSITIS OSSIFICANS PROGRESSIVA.

Authors:  J Rosenstirn
Journal:  Ann Surg       Date:  1918-11       Impact factor: 12.969

3.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

4.  An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.

Authors:  Salin A Chakkalakal; Deyu Zhang; Andria L Culbert; Michael R Convente; Robert J Caron; Alexander C Wright; Andrew D A Maidment; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

Review 5.  Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis.

Authors:  Frederick S Kaplan; Vitali Y Lounev; Haitao Wang; Robert J Pignolo; Eileen M Shore
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

Review 6.  Inherited human diseases of heterotopic bone formation.

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Nat Rev Rheumatol       Date:  2010-08-10       Impact factor: 20.543

7.  Derailing heterotopic ossification and RARing to go.

Authors:  Frederick S Kaplan; Eileen M Shore
Journal:  Nat Med       Date:  2011-04       Impact factor: 53.440

8.  When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Jay Groppe; Eileen M Shore
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 9.  Applications of small molecule BMP inhibitors in physiology and disease.

Authors:  Charles C Hong; Paul B Yu
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-14       Impact factor: 7.638

Review 10.  Fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Martine Le Merrer; David L Glaser; Robert J Pignolo; Robert E Goldsby; Joseph A Kitterman; Jay Groppe; Eileen M Shore
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098
View more
  1 in total

Review 1.  Bone Morphogenetic Proteins.

Authors:  Takenobu Katagiri; Tetsuro Watabe
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-06-01       Impact factor: 10.005
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.